<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Zeina A Althanoon</style></author><author><style face="normal" font="default" size="100%">Imad AJ Thanoon</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparative Effects of Amlodipine and Candesartan on Blood Pressure and Metabolic Profile in Non-Diabetic Hypertensive Patients</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">February 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">141-147</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction:&lt;/strong&gt; The present study aimed to compare the effects of the angiotensin II receptor blocker candesartan and the calcium channel blocker amlodipine on blood pressure and metabolic profile in nondiabetic hypertensive patients. &lt;strong&gt;Methods: &lt;/strong&gt;The study involved non-diabetic patients with mild to moderate hypertension. They were randomly assigned to receive candesartan or amlodipine for 24 weeks, parameters were evaluated at baseline and after 12 weeks and 24 weeks for each patient group. &lt;strong&gt;Results:&lt;/strong&gt; Candesartan and amlodipine both reduced blood pressure and the HOMA-IR index significantly (P &amp;lt; 0.05, 24 weeks vs. baseline). Candesartan was more effective than amlodipine in lowering blood pressure and HOMA-IR, although the difference was not significant statistically.&lt;strong&gt; Conclusion:&lt;/strong&gt; Both candesartan and amlodipine are extremely effective at reducing blood pressure in moderate hypertension patients. Candesartan cilexetil has a major benefit in terms of tolerability, as it reduces the risk of developing metabolic dysregulation.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Key words:&lt;/strong&gt; Amlodipine, Candesartan, Hypertension, Insulin resistance.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">141</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Zeina A Althanoon&lt;sup&gt;1,*&lt;/sup&gt;, Imad AJ Thanoon&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;College of Pharmacy, University of Mosul, Mosul, IRAQ.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;College of Medicine, University of Mosul, Mosul, IRAQ.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Akram A Hammo</style></author><author><style face="normal" font="default" size="100%">Abdulla A Ahmad</style></author><author><style face="normal" font="default" size="100%">Zeina A Althanoon</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Role of Gender in the Protection Against Doxorubicin-Induced Oxidative Stress</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Coenzyme Q10</style></keyword><keyword><style  face="normal" font="default" size="100%">Doxorubicin</style></keyword><keyword><style  face="normal" font="default" size="100%">Gender difference</style></keyword><keyword><style  face="normal" font="default" size="100%">Oxidative stress</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">782-788</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; There are gender differences in the oxidation-reduction reactions. Doxorubicin (Dox) is a chemotherapeutic drug that can produce oxidative stress which may require prevention by antioxidants. Aim: The study aimed to investigate the gender-dependent changes in Dox-induced oxidative stress, and the protective effects of coenzyme Q10 (CoQ10).&lt;strong&gt; Materials and Methods&lt;/strong&gt;: Rats were administered CoQ10 orally for 17 days. On day 13, some rats receiving CoQ10 received a single intraperitoneal dosage of Dox, whereas other rats received normal saline. Glutathione (GSH), malondialdehyde (MDA), and total anti-oxidant capacity (T-AOC) were measured in both genders of albino rats. &lt;strong&gt;Results&lt;/strong&gt;: Dox significantly reduced both GSH and T-AOC levels and caused a significant increase in MDA. The administration of CoQ10 significantly prevented these changes. Dox caused a larger reduction in GSH in males than in females, while CoQ10 caused more protection in females. Dox caused a higher increase in MDA levels in males.&lt;strong&gt; Conclusion:&lt;/strong&gt; Pre-treatments with CoQ10 may protect against Dox-induced oxidative stress, with gender-dependent variations in the extent of these Dox/CoQ10 effects.&lt;/p&gt;
&lt;quillbot-extension-portal&gt;&lt;/quillbot-extension-portal&gt;</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Research Article </style></work-type><section><style face="normal" font="default" size="100%">782</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Akram A Hammo&lt;sup&gt;1&lt;/sup&gt;, Abdulla A Ahmad&lt;sup&gt;2,*&lt;/sup&gt;, Zeina A Althanoon&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;The primary health care sector in Al-Baaj, Nineveh Health Directorate, Ministry of Health, IRAQ.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of clinical and laboratory sciences, College of Pharmacy, University of Mosul, IRAQ.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of pharmacology and toxicology, College of Pharmacy, University of Mosul, IRAQ&lt;/p&gt;
&lt;quillbot-extension-portal&gt;&lt;/quillbot-extension-portal&gt;</style></auth-address></record></records></xml>